205 related articles for article (PubMed ID: 36037847)
1. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
3. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
4. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients.
Fernández-Alvarez P; Guerra-Veloz MF; Vilches-Arenas A; Cordero-Ruíz P; Bellido-Muñoz F; Caunedo-Alvarez A; Carmona-Soria I
Viruses; 2023 May; 15(6):. PubMed ID: 37376551
[No Abstract] [Full Text] [Related]
6. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
[TBL] [Abstract][Full Text] [Related]
7. Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.
Lourenço MS; Zitelli PMY; Cunha-Silva M; Oliveira AIN; Lima RGR; Souza EO; Oliveira CP; Sevá-Pereira T; Carrilho FJ; Pessoa MG; Mazo DF
Clinics (Sao Paulo); 2021; 76():e3186. PubMed ID: 34817045
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ; Tran S; Huang CF; Hsu YC; Preda C; Toyoda H; Liu J; Jun DW; Landis C; Huang DQ; Gila A; Negoita L; Yasuda S; Tseng CH; Tsai PC; Uojima H; Nozaki A; Chuma M; Atsukawa M; Ishigami M; Itokawa N; Iio E; Lam CP; Watanabe T; Asai A; Yokohama K; Abe H; Enomoto M; Kawada N; Tamori A; Lee DH; Jun MJ; Do S; Vo DKH; Liu L; Li J; Ji F; Wang W; Li Y; Wang X; Guo F; Xu Q; Jing L; Ye Q; Pan H; Zhang J; Wen X; Wang Q; Ren H; Cai D; Shang J; Liu J; Lu C; Zang W; Li J; Niu J; Zhang M; Wu C; Huang R; Maeda M; Nakanishi A; Yeh ML; Chuang WL; Huang JF; Dai C; Ishikawa T; Takaguchi K; Senoh T; Trinh HN; Takahashi H; Eguchi Y; Quek SXZ; Haga H; Ogawa E; Wong G; Buti M; Fukunishi S; Ueno Y; Yuen MF; Tanaka Y; Lim SG; Cheung R; Yu ML; Nguyen MH
Hepatol Int; 2023 Oct; 17(5):1150-1161. PubMed ID: 37273170
[TBL] [Abstract][Full Text] [Related]
10. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
12. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
Corma-Gómez A; Macías J; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Santos M; Real LM; Palacios R; Santos IL; Geijo P; Imaz A; Merino D; Galindo MJ; Reus-Bañuls S; López-Ruz MÁ; Galera C; Pineda JA;
AIDS; 2021 Nov; 35(13):2119-2127. PubMed ID: 34049354
[TBL] [Abstract][Full Text] [Related]
14. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
15. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
[TBL] [Abstract][Full Text] [Related]
16. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
19. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.
Pearlman BL
Dig Dis Sci; 2024 May; 69(5):1551-1561. PubMed ID: 38580885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
